San Diego-based Jecure Therapeutics and its inflammatory disease platform has been snapped up by Genentech, it was announced Nov. 27.

Deal terms were not disclosed.

Jecure launched in 2015 with a $20 million series A round from Versant Ventures. Funding was for new therapeutics in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Genentech will gain the rights to Jecure’s preclinical portfolio of NLRP3 inhibitors, which are linked with the onset and progression of various inflammatory diseases, including liver diseases.

“We’re excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with inflammatory diseases,” said James Sabry, global head of pharma partnering at Roche.

Genentech is a subsidiary of Roche.

Jecure has 15 employees. CEO Jeffrey Stafford was the chief scientific officer of Quanticel Pharmaceuticals, a cancer company that sold in 2015 to Celgene.